

36 quantitative measurements with decreasing dose. An increase in the ^2H -water signal over time
37 particularly in the liver, could be used as an indirect measure of metabolism.

38 **Conclusion**

39 DMI of the human abdomen is feasible using a routine MRI system and the metabolism measured in
40 the kidney and liver can serve as a reference for future clinical studies. The ^2H -glucose dose can be
41 reduced from 0.75 to 0.25 g/kg to minimize gastric signal without substantially affecting the
42 reliability of organ quantification.

43

44

45 **Introduction**

46

47 Aerobic glycolysis, or the Warburg effect, occurs in a wide range of cancers and describes the increase
48 in glucose breakdown which occurs even in the presence of abundant oxygen¹. This effect is
49 characterized by upregulated glucose consumption and the formation of downstream lactate that
50 accumulates in the extracellular space, creating a hostile acidic extracellular tumor environment. A
51 number of novel metabolic MRI methods have recently emerged to exploit this metabolism which
52 have the potential for identifying more aggressive tumor subtypes and for assessing early metabolic
53 response to treatments²⁻⁵.

54 In 2018, deuterium metabolic imaging (DMI) emerged as one of these non-invasive methods to assess
55 glycolytic metabolism in the brain and cerebral tumors⁶. Unlike conventional proton (¹H) MRI,
56 deuterium (²H) is found at very low natural abundance (~0.01%), and therefore deuterium spectra
57 contain almost no background signal apart from the large peak arising from naturally-abundant, and
58 partially-deuterated water (²H-water) signal, with some smaller deuterated peaks from adipose tissue.
59 DMI exploits this low background signal through the administration of exogenous ²H-labelled
60 molecules such as ²H-glucose ([6,6'-²H₂]glucose)⁷⁻¹¹. This labelled glucose is very safe¹² and can be
61 conveniently administered orally, thereby facilitating clinical use of the technique (Fig. 1a). Following
62 absorption in the gastrointestinal tract, ²H-glucose metabolism can be followed spatially and
63 temporally using deuterium magnetic resonance spectroscopic imaging (²H-MRSI)^{6,9}.

64 Despite having great potential for assessing glycolysis, DMI has faced several challenges in its
65 translation into clinical field strength^{7,13}. Whilst DMI has recently been translated to 3 T in the
66 brain^{9,14}, DMI outside of the brain suffers from additional challenges including: increased tissue
67 inhomogeneity, motion, poor shimming, prominent gastric signal from the oral probe, and overlap
68 between the naturally-abundant lipid peak and the tumor ²H-lactate signal, all of which reduce
69 spectral quality. For these reasons, abdominal DMI has only been conducted at 7 T to date^{8,10}.


70 In this study, we have addressed these challenges and conducted abdominal DMI in healthy volunteers
71 at 3 T. The oral ²H-glucose dose has been varied to explore the optimal dose required for clinical
72 imaging, to reduce both the cost and the gastric signal arising from the oral ingestion of the probe,
73 without affecting the desired signal from the abdominal organs¹⁵. We demonstrate the feasibility of
74 quantitative abdominal DMI of the liver and kidney at clinical field strength and present a robust
75 pipeline for assessing ²H-glucose spectra for future clinical use including novel metrics of
76 metabolism.

77

		² H-Glucose [g]	Dose [g/kg]	Dose label	Age range [a]	Sex	Height [cm]	Weight [kg]	BMI [kg/m ²]
Vol 1	Visit 1	60.00	0.69	high	26-30	m	192	87.0	23.6
	Visit 2	40.00	0.46	medium					
	Visit 3	20.00	0.23	low					
Vol 2	Visit 1	20.00	0.19	low	26-30	m	189	108.0	30.2
	Visit 2	60.00	0.56	high					
Vol 3	Visit 1	40.00	0.50	medium	20-25	m	187	80.0	22.9
	Visit 2	60.00	0.75	high					
	Visit 3	19.55	0.25	low					
Vol 4	Visit 1	40.88	0.75	high	26-30	f	164	54.5	20.3
	Visit 2	13.50	0.25	low					
Vol 5	Visit 1	33.50	0.50	medium	26-30	m	184	67.0	19.8
	Visit 2	50.18	0.75	high					
	Visit 3	17.00	0.25	low					

78 **Table 1 | Demographics.** Details about the individual volunteers and the dose received at each visit.

79



80

81 **Figure 1 | Study schema and experimental procedure.** (a) DMI as a technique. A solution
 82 containing ²H-glucose is prepared and orally administered, followed by spectroscopic imaging.
 83 (b) n = 5 volunteers were imaged on two (n = 2) or three (n = 3) different days, totalling 13 imaging
 84 sessions. At each visit, the volunteers received one of three dose regimens of the ²H-glucose.

85

86

87 **Materials and Methods**

88 **Study Design**

89

90 The study was approved by a local research ethics committee (23/YH/0127) and all five recruited
91 healthy volunteers (4 male, 1 female, age range = 20-30, Table 1) gave informed consent in writing.
92 To assess the effect of dose reduction, the volunteers underwent up to three DMI studies on different
93 days, receiving different doses of ^2H -glucose (Cambridge Isotope Laboratories Inc., Tewksbury, MA),
94 dissolved in water for injection (B. Braun, Melsungen, Germany), as shown in Table 1. The three dose
95 regimens chosen for this study include the current standard dose given to volunteers and patients in
96 previously published studies^{9,11} (“high”), as well as a dose reduction of one-third (“medium”) and
97 two-thirds (“low”) of the standard dose. The “high” dose corresponds to 0.75 g/kg, with a maximum
98 administration of 60 g. All five volunteers received the high and the low dose, while three volunteers
99 also received the medium dose, totalling $n = 13$ DMI sessions. The volunteers were fasted for 6 h pre-
100 scan. Prior to, and immediately after each exam, blood pressure, heart rate, blood oxygen saturation,
101 and blood glucose level were recorded (Fig. S1).

102

103 **^2H -MR Spectroscopy and Imaging**

104

105 The volunteers were positioned supine in the MRI (3 T Premier, GE Healthcare, Chicago, IL) head-
106 first. A flexible 20x30 cm² ^2H -transmit-receive surface coil (RAPID Biomedical, Rimpar, Germany)
107 was wrapped around the right side of the abdomen, and fixed via Velcro straps, with the center of the
108 coil positioned between the liver and kidney. An axial T_1 -weighted volume (LAVA-flex) was acquired
109 for co-registration using the built-in body coil. Subsequently, a series of Hamming-filtered density-
110 weighted ^2H -MRSI (real matrix size = 10x10x10, 1678 interleaves, FOV = 40 cm, FA = 60°, TE = 0.7
111 ms, TR = 250 ms) were acquired for ≤ 90 min, interleaved between acquisitions, by the collection of
112 unlocalized ^2H spectra (TE = 0.7 ms, TR = 600 ms, FA = 90°, 64 averages).

113

114 **Data Processing and Analysis**

115

116 Spectra were zero-filled by a factor of two in all three spatial dimensions and fitted automatically using
117 a customised version of OXSA-AMARES^{16,17} with an SNR threshold of five. For display in Fig. 5,
118 spatial interpolation by a factor of 12.8 in plane and a factor of 2 in the z-dimension was conducted.
119 Voxels were manually assigned to the respective organs using an overlay of the summed ^2H -signal and

120 the axial anatomical LAVA-flex ¹H localizer (FOV = 48 cm, FA = 12°, TEs = 1.1/2.2 ms, TR = 3.96
121 ms), as seen in Fig. 3. For liver, kidney, and duodenum, the prior knowledge of the fitting routine
122 included three peaks: ²H-water, ²H-glucose, and ²H-lipid+lactate, as those commonly expected for DMI
123 studies in the abdomen¹⁰. For the stomach, the prior knowledge was set to detect only one peak, assumed
124 to be ²H-glucose in the absence of metabolism. Peak amplitudes, as fitted by OXSA-AMARES, were
125 used to calculate the GGW and LLW (equation 1 and 2) ratio for every organ and timepoint using
126 MATLAB (MathWorks, Natick, MA). The GGW and LLW ratio represent the respective normalization
127 of ²H-glucose and ²H-lipid+lactate signals against the naturally abundant ²H-water peak to compare
128 across scans as defined in equations 1 and 2:

129
$$GGW(t) = \frac{gluc(t)}{gluc(t)+wat(t)} \quad \text{equation 1}$$

130
$$LLW(t) = \frac{liplac(t)}{liplac(t)+wat(t)} \quad \text{equation 2}$$

131 with gluc(t), liplac(t) and wat(t) representing the ²H-glucose, ²H-lipid+lactate (whose peaks overlap)
132 and ²H-water signals at the respective timepoints. The GGW provides a normalized metric of ²H-glucose
133 uptake, which is comparable across participants as a potentially useful clinical measurement. LLW is a
134 similar comparative metric, which at baseline is dominated by the lipid signal and any increase over
135 time corresponds to lactate formation in the organ of interest. For quantitative analysis of the
136 timecourses, GGW_{max}, GGW_{AUC}, and GGW_{mean plateau} were calculated. GGW_{max} was determined by
137 taking the maximum GGW value in each organ timecourse. For GGW_{AUC}, the GGW value of each
138 timepoint t_n was multiplied by the time difference $t_n - t_{n-1}$ between the previous timepoint in minutes
139 (equation 3). The separate AUC(t) values were then summed until $t = 74$ min, which was a common
140 timepoint across volunteers and exams, to make the GGW_{AUC} comparable across volunteers and across
141 scans:

142
$$GGW_{AUC}(x) = \sum_{n=1}^x GGW(t_n) \cdot (t_n - t_{n-1}); \text{ with } t_x = 74 \text{ min} \quad \text{equation 3}$$

143 GGW_{mean plateau} was determined by taking the mean GGW of all timepoints after signal plateauing. The
144 plateau time was determined to be $t = 30$ min for liver, and $t = 40$ min for kidney, broadly aligning with
145 previously published studies¹⁰. For unlocalized spectroscopy, the GGW_{mean plateau} was replaced by
146 GGW_{mean} over the whole timecourse, since the detection of signal build-up, and subsequent plateauing,
147 was not possible for all scans, depending on the contribution of the stomach to the overall detected
148 signal. For statistical analysis, Analysis of Variance (ANOVA) was performed in GraphPad Prism
149 (GraphPad Software, Boston, MA), followed by Tukey's Honestly Significant Difference (HSD) test as
150 post-hoc analysis.

151

152 **Results**

153 **Unlocalized Spectroscopy**

154

155 Unlocalized spectra showed good SNR (> 5) for all three dose regimens, with the ^2H -water (4.7 ppm)
156 and ^2H -glucose (3.7 ppm) peaks being clearly resolved at clinical field strength (Fig. 2a-c).

157 Interestingly, the GW ratio derived from these unlocalized spectra showed ^2H -glucose build-up
158 steadily over time in some volunteers, while appearing early in others (Fig. 2d). This is because,

159 depending on the coil positioning, the stomach and duodenum were detectable in some cases,

160 resulting in an early and high ^2H -glucose signal in some cases. The low dose regimen exhibited a

161 lower GW across all metrics (Fig. 2e; $\text{GGW}_{\text{max}} = 0.44 \pm 0.03$; $\text{GGW}_{\text{mean}} = 0.35 \pm 0.05$; $\text{GGW}_{\text{AUC}} =$

162 24.1 ± 5.0 ; $n = 4$) compared to the medium ($\text{GGW}_{\text{max}} = 0.55 \pm 0.07$, $p = 0.0902$; $\text{GGW}_{\text{mean}} = 0.48 \pm$

163 0.05 , $p = 0.0193$; $\text{GGW}_{\text{AUC}} = 28.8 \pm 2.7$; $p = 0.5097$, $n = 3$) and the high doses ($\text{GGW}_{\text{max}} = 0.57 \pm$

164 0.07 , $p = 0.0247$; $\text{GGW}_{\text{mean}} = 0.47 \pm 0.05$, $p = 0.0148$; $\text{GGW}_{\text{AUC}} = 33.8 \pm 6.4$, $p = 0.0560$; $n = 5$).


165 Statistically significant results are indicated in Fig. 2e. Notably, there was no significant difference in

166 quantitative values between the medium and the high dose across all the metrics. The dynamics of the

167 fitted ^2H -glucose signal amplitude showed a signal build-up over 60 min in most cases (Fig. 2f). An

168 increase in the ^2H -water signal over time could be observed in all cases, ranging from 10-56% when

169 comparing the last timepoint with the first in each case (Fig. 2g-h, Fig. S2).



170

171 **Figure 2 | Dynamic unlocalized spectroscopy acquired from the healthy abdomen after oral**
 172 **administration of ^2H -glucose. (a-c)** Spectral timecourses demonstrating ^2H -water and ^2H -glucose
 173 peaks from a single volunteer (#3) after receiving the following ^2H -glucose doses: (a) high; (b)
 174 medium; (c) low. **(d)** Timecourse of GGW (see methods) for each volunteer at each visit. **(e)** The three
 175 different quantitative measures we have introduced to evaluate ^2H -glucose signal over time (see
 176 methods). **(f)** The total ^2H -glucose signal initially increases with respect to the first timepoint in all
 177 volunteers and starts to decline after ~ 50 -60 minutes. **(g)** The ^2H -water grows moderately over time in
 178 all volunteers, hinting suggesting the production of water through metabolism. **(h)** First (start) vs. last
 179 (end) timepoint of the data shown in (g), to demonstrate that all volunteers exhibit a growth in the ^2H -
 180 water signal, thus suggesting a consistent effect.

181


182 Imaging

183

184 Anatomically constrained ^2H signal was identified in the liver and kidney on MRSI in all cases ($n =$
 185 13; Fig. 3), and in the stomach and duodenum in most cases ($n = 10$ and 11 respectively). Only ^2H -
 186 glucose could be detected in the stomach, while the duodenum exhibited a small but detectable ^2H -

187 water peak. The kidney exhibited a small lipid peak which was probably secondary to partial volume
188 effects from the surrounding visceral fat.

189 The timecourses for the kidney (Fig. 4a) and the liver (Fig. 4b) showed a build-up in the GGW ratio,
190 with the liver plateauing earlier at ~30 min, compared to the kidney at ~40 min. GGW signal in the
191 duodenum remained high throughout the whole timecourse (Fig. 4c). The raw or non-normalized ^2H -
192 glucose signal was assessed in the stomach due to the low ^2H -water signal, which showed a decrease
193 over time in all cases as gastric emptying occurred (Fig. 4d).



194

195 **Figure 3 | Representative images derived from spatially resolved spectroscopy.** The summed ^2H
196 signal is shown as a colorscale image with single-voxel spectra from each organ (volunteer 5, $t = 33$
197 min after receiving the high (gold) and the medium (blue) doses. Stomach and duodenal ROIs are
198 dominated by the ^2H -glucose signal, whereas kidney and liver exhibit a prominent ^2H -water peak as
199 well as a small lipid peak in the kidney. The boxes in the images indicate non-interpolated voxel sizes.

200

201 **Comparison between the liver and kidney, and between doses**

202

203 Across all three dose regimens and all three quantitative metrics, the liver exhibited a significantly
204 higher ^2H -glucose uptake than the kidney (Fig. 4e-h, p-values for $\text{GGW}_{\text{max}}/\text{GGW}_{\text{mean plateau}}/\text{GGW}_{\text{AUC}}$:
205 0.0097/0.0032/0.0044). Furthermore, all three values increased with dose in both the liver and kidney.
206 Notably, this trend was statistically significant between the low dose and the other two doses, but not
207 between the high and the medium dose. Relevant p-values are shown in Figure S3. Example imaging
208 timecourses from volunteer 5 for all three doses are displayed in Figure 5.

209



210 **^2H -lipid content and ^2H -lactate formation**

211

212 The ^2H -lactate signal appears at a similar chemical shift as the ^2H -lipid signal (both at ~ 1.3 ppm)¹⁸,
213 and as lipid is particularly abundant in the abdomen^{19,20} this presents a challenge for the accurate
214 quantification of ^2H -lactate. Hence, it is more important to characterize the naturally abundant lipid
215 signal on abdominal DMI, compared to the brain where the majority of previous DMI research has
216 been undertaken.


217 A small ^2H -lipid peak was identified in voxels overlying the kidney, and to a lesser extent the liver,
218 which was likely due to partial volume effects from the visceral fat surrounding these organs (Fig. 3).
219 The LLW ratio was calculated and the respective timecourses for both organs are displayed in Fig.
220 4i/j. The lipid content was higher in the kidney (mean across all volunteers and timepoints: $0.27 \pm$
221 0.10) compared to the liver (0.21 ± 0.08).

222 Lactate plays an important role in many pathological processes and therefore it is key to quantify the
223 background ^2H -lactate signal derived from normal organs after oral administration of ^2H -glucose as a
224 reference. Fig. 6a shows the normalized ^2H -lipid+lactate signal for the three volunteers that were
225 administered all three doses. A direct comparison of the last timepoint compared to the first for all
226 volunteers can be seen in Fig. 6b-c. In the liver, the ^2H -lipid+lactate signal increased in 12/13
227 examinations, with an average increase of $38.5 \pm 24.2\%$ showing that the healthy liver exhibits
228 detectable ^2H -lactate 60-80 min after administering oral ^2H -glucose. In contrast, the ^2H -lipid+lactate
229 signal increased in only 8/13 examinations in the kidney, with an average increase of only $5.0 \pm 17\%$,
230 suggesting very little lactate formation in this timescale.



	GGW_{AUC}			$GGW_{mean\ plateau}$			GGW_{max}		
	high dose	medium dose	low dose	high dose	medium dose	low dose	high dose	medium dose	low dose
liver	31.3 ± 2.6	29.5 ± 1.8	26.6 ± 2.2	0.51 ± 0.01	0.48 ± 0.02	0.43 ± 0.02	0.54 ± 0.02	0.51 ± 0.02	0.48 ± 0.03
kidney	26.5 ± 2.6	25.3 ± 2.5	22.4 ± 2.6	0.46 ± 0.02	0.42 ± 0.02	0.34 ± 0.03	0.49 ± 0.04	0.46 ± 0.04	0.41 ± 0.05
duodenum	51.5 ± 5.0	53.9 ± 3.9	49.1 ± 3.6	0.76 ± 0.06	0.78 ± 0.07	0.70 ± 0.10	0.86 ± 0.07	0.85 ± 0.05	0.85 ± 0.04

h



232 **Figure 4 | Quantitative evaluation of imaging data. (a-c)** GGW timecourses for ^2H -glucose signal
233 in the kidney (a), liver (b) and duodenum (c). **(d)** ^2H -glucose signal in the stomach over time shows a
234 decrease likely to correspond to gastric emptying. **(e-g)** Quantitative measures of GGW_{AUC} (e),
235 $\text{GGW}_{\text{mean plateau}}$ (f) and GGW_{max} (g) exhibit dose dependence in the liver and kidney, whereas they
236 remain elevated in the duodenum regardless of dose. **(h)** Summarized quantitative values displayed in
237 (e-g). **(i,j)** ^2H -lipid signal, as evaluated by the LLW parameter (see methods) over time. The kidney (i)
238 shows a generally higher LLW than the liver (j), indicating a higher lipid content inside the imaged
239 kidney voxels, which is likely to arise from the surrounding visceral fat.


240

241 ^2H -water signal increase as an indirect measure of metabolism


242

243 The unlocalized spectroscopy showed an increase in ^2H -water signal over time (Fig. 2g-h), which has
244 been reported in previous preclinical and clinical studies^{9,10,21}. Spectroscopic imaging was
245 subsequently used to localize this signal increase; Fig. 6d shows the normalized ^2H -water signal for
246 the three volunteers that were administered all three doses. A direct comparison of the last timepoint
247 compared to the first for all volunteers can be seen in Figures 6e-f. In the kidney, the ^2H -water signal
248 increased over time in 10/13 examinations, with an average increase of $10.3 \pm 12.8\%$. In the liver, the
249 ^2H -water signal increased in all 13 examinations, with an average increase of $17.6 \pm 9.7\%$. Hence, the
250 liver is likely driving the ^2H -water signal increase in the unlocalized spectroscopy data. Indeed, the
251 three examinations with the largest ^2H -water signal increases in the unlocalized spectra were the same
252 three examinations that exhibited the largest ^2H -water signal increase in the liver imaging data. This
253 observation further confirms the conclusion, that the liver is causing the dominant part of the ^2H -water
254 signal increase in the unlocalized spectra.

liver/stomach




kidney/duodenum



255

256 **Figure 5 | Imaging timecourses for ^2H -glucose for all three dose regimens administered to**
257 **volunteer 5. (a)** A slice containing both the liver and stomach showing declining ^2H -glucose signal in
258 the stomach and increasing signal in the liver. **(b)** A slice containing both the kidney and the
259 duodenum: the kidney shows a build-up of ^2H -glucose, whereas the duodenum signal shows little
260 variation in signal intensity over time. Timecourses of the ^2H -water signal, as well as the summed ^2H -
261 signal can be viewed in the supplementary information (Fig. S4, S5).

262



263

264 **Figure 6 | ^2H -water and ^2H -lipid+lactate signal derived from individual volunteers over time,**
 265 **extracted from the imaging data. (a) ^2H -lipid+lactate signal from the three volunteers that**
 266 **underwent all three imaging sessions. Unlike the kidney, the liver showed a trend towards an**
 267 **increasing signal over time, up to x2.5 the initial value. (b,c) Comparison of the first and last**
 268 **timepoints from all the volunteers reveals a trend towards increasing ^2H -lipid+lactate signal in the**
 269 **liver (c), whereas the kidney (b) shows no trend across volunteers. The liver data suggests the hepatic**
 270 **formation of ^2H -lactate from ^2H -glucose in the timecourse of the experiment. (d) Comparative ^2H -**
 271 **water signal of the same three volunteers. The liver shows a clear and consistent increase in ^2H -**
 272 **water signal over time. (e,f) Comparison of the first and last timepoints from all the volunteers reveals a**

273 trend towards increasing ^2H -water signal in both kidney (e) and liver (f) over time. In the case of the
274 liver, the ^2H -water signal increased in all volunteers.

275 Discussion

276

277 Deuterium metabolic imaging is an emerging method for probing tissue metabolism with potential
278 applications in a wide range of diseases given the importance of glucose utilization in both health and
279 disease. Here we translate the technique to the abdomen at clinical field strength, showing its
280 feasibility for assessing hepatic and renal metabolism. We also optimize the dose of oral ^2H -glucose
281 for clinical use and present metrics to quantitatively evaluate its uptake and metabolism in tissues.

282 The signal from ^2H -glucose was evaluated up to 90 min after oral administration and could be used to
283 evaluate accumulation and absorption in the stomach and duodenum. Importantly, the use of a surface
284 coil in combination with its positioning around the right side of the abdomen was used to minimize
285 unwanted gastric signal when imaging the liver and kidney. The liver generally exhibited a higher ^2H -
286 glucose signal compared to the kidney, rapid plateauing of the signal, more reproducible time curves,
287 and a lower lipid signal, therefore making it a promising organ to be assessed using DMI.

288 The increase in ^2H -water signal over time is likely to arise from water derived from glucose
289 metabolism^{22,23}. The liver showed a higher ^2H -glucose uptake than the kidney, as well as the formation
290 of a small ^2H -lipid+lactate signal, in keeping with increased hepatic metabolism. A confounder when
291 analyzing DMI data is that the long timecourse for acquisition allows for metabolites from other
292 organs to be washed into the organ under assessment so the measured signal may not be due to
293 metabolism in the organ under investigation.

294 The doses of ^2H -glucose used in DMI range from 60-75 g^{8-11,24}, with 75 g being the standard dose for
295 a clinical glucose tolerance test²⁵. The blood glucose is transiently increased during these dose
296 regimens, and we show that this could be avoided by lowering the dose to ~20 g, allowing steady state
297 metabolism to be probed without a substantial loss in signal (Fig. S1). This reduces the cost of DMI as
298 well as the risk of unwanted gastric signal contaminating the quantification from other organs.

299 As an emerging technique, the best approaches for quantitative assessment and kinetic modelling of
300 DMI are yet to be determined. The challenges are similar to other time-resolved metabolic imaging
301 methods, such as those found in the analysis of positron emission tomography (PET)²⁶ and
302 hyperpolarized ^{13}C -MRI data^{27,28}. However, DMI also presents some problems unique to the technique
303 and here we have proposed three novel quantitative biomarkers for assessment of this dynamic data:
304 GGW_{AUC} , $\text{GGW}_{\text{mean plateau}}$, and GGW_{max} . The results show that the hepatic and renal measurements are
305 influenced by the administered dose but do not scale with it, suggesting a rate limiting element in

306 delivery and metabolism. It is interesting to note that, despite the range of doses given across different
307 volunteers, the duodenal measurements are remarkably constant over time and between individuals.

308 The increase in the ^2H -lipid+lactate signal observed in the liver is likely to be from lactate formation
309 as lipogenesis occurs on a slower timescale²⁹. The lipid signal demonstrates a low SNR and has a
310 broader linewidth compared to the ^2H -water and ^2H -glucose and may be overestimated while fitting
311 with the automated approach here, which calculates a peak area.

312 One limitation of this study is the small cohort size; extending this study into larger cohorts and
313 undertaking formal repeatability and reproducibility studies in a multisite setting will be important for
314 future research in this field. Normalized plots have been referenced to the first timepoint of the same
315 exam and this reference timepoint differed across examinations. It would be advantageous to
316 reference the ^2H -water and ^2H -lipid signals against the naturally abundant measurements at baseline,
317 but as the participants were repositioned after drinking in the upright position, the exact placement of
318 the coil could change, potentially resulting in misregistration. Future studies could overcome this by
319 maintaining the participant on the scanner with the coil in position and administering the ^2H -glucose
320 using a straw⁸, allowing the natural abundance scan to be directly compared to the post-administration
321 images. Intravenous injection of ^2H -glucose could also be considered in the future, bypassing
322 gastrointestinal uptake, which would reduce the required dose further and lead to more rapid substrate
323 delivery. However, this may result in a transient supraphysiological dose of glucose which could alter
324 tissue metabolism.

325

326 **Conclusion**

327 In conclusion, these data demonstrate the feasibility of quantitative DMI in the kidney and liver at
328 clinical field strength, without signal interference by the stomach. Furthermore, we show that the
329 administered dose can be significantly reduced, reducing the costs of a DMI scan and the otherwise
330 dominant gastric signal, which are important considerations for future clinical use. Additionally, we
331 introduced new methodology to assess glucose uptake and metabolism, which could be used to
332 quantify tissue metabolism in disease settings.

333

334

335 **Acknowledgements**

336

337 PW acknowledges support from the Gates Cambridge Trust (#OPP1144). MM acknowledges support
338 from the Cambridge Experimental Cancer Medicine Centre. This research was further supported by
339 Cancer Research UK (CRUK; C19212/A27150; C19212/A29082), CRUK Cambridge Centre,
340 Wellcome Trust, NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). The views
341 expressed are those of the authors and not necessarily those of the NIHR or the Department of Health
342 and Social Care. The authors also acknowledge support from the National Cancer Imaging
343 Translational Accelerator (NCITA) and The Mark Foundation Institute for Integrative Cancer
344 Medicine (MFICM) at the University of Cambridge.

345

346

347 **References**

348

- 349 1. Warburg, O. ueber den Stoffwechsel der Carcinomzelle. *Naturwissenschaften* **12**, 1131–1137
350 (1924) doi: 10.1007/BF01504608.
- 351 2. Tekade, R. K. & Sun, X. The Warburg effect and glucose-derived cancer theranostics. *Drug*
352 *Discov. Today* **22**, 1637–1653 (2017) doi: 10.1016/j.drudis.2017.08.003.
- 353 3. Hesketh, R. L. & Brindle, K. M. Magnetic resonance imaging of cancer metabolism with
354 hyperpolarized ¹³C-labeled cell metabolites. *Curr. Opin. Chem. Biol.* **45**, 187–194 (2018) doi:
355 10.1016/j.cbpa.2018.03.004.
- 356 4. Kreis, F. *et al.* Measuring Tumor Glycolytic Flux in Vivo by Using Fast Deuterium MRI.
357 *Radiology* **294**, 289–296 (2020) doi: 10.1148/radiol.2019191242.
- 358 5. Low, J. C. M. *et al.* Deuterium metabolic imaging differentiates glioblastoma metabolic subtypes
359 and detects early response to chemoradiotherapy. *Cancer Res.* (2024) doi:10.1158/0008-
360 5472.CAN-23-2552 doi: 10.1158/0008-5472.CAN-23-2552.
- 361 6. De Feyter, H. M. *et al.* Deuterium metabolic imaging (DMI) for MRI-based 3D mapping of
362 metabolism in vivo. *Sci. Adv.* **4**, eaat7314 (2018) doi: 10.1126/sciadv.aat7314.

- 363 7. De Feyter, H. M. & De Graaf, R. A. Deuterium metabolic imaging – Back to the future. *J. Magn.*
364 *Reson.* **326**, 106932 (2021) doi: 10.1016/j.jmr.2021.106932.
- 365 8. Poli, S. *et al.* Interleaved trinuclear MRS for single-session investigation of carbohydrate and
366 lipid metabolism in human liver at 7T. *NMR Biomed.* **37**, e5123 (2024) doi: 10.1002/nbm.5123.
- 367 9. Kaggie, J. D. *et al.* Deuterium metabolic imaging and hyperpolarized ¹³C-MRI of the normal
368 human brain at clinical field strength reveals differential cerebral metabolism. *NeuroImage* **257**,
369 119284 (2022) doi: 10.1016/j.neuroimage.2022.119284.
- 370 10. Gursan, A. *et al.* Deuterium body array for the simultaneous measurement of hepatic and renal
371 glucose metabolism and gastric emptying with dynamic 3D deuterium metabolic imaging at 7 T.
372 *NMR Biomed.* **36**, e4926 (2023) doi: 10.1002/nbm.4926.
- 373 11. Khan, A. S. *et al.* Deuterium Metabolic Imaging of Alzheimer Disease at 3-T Magnetic Field
374 Strength: A Pilot Case-Control Study. *Radiology* **312**, e232407 (2024) doi:
375 10.1148/radiol.232407.
- 376 12. Jones, P. J. H. & Leatherdale, S. T. Stable isotopes in clinical research: safety reaffirmed. *Clin.*
377 *Sci.* **80**, 277–280 (1991) doi: 10.1042/cs0800277.
- 378 13. Graaf, R. A. *et al.* On the magnetic field dependence of deuterium metabolic imaging. *NMR*
379 *Biomed.* **33**, e4235 (2020) doi: 10.1002/nbm.4235.
- 380 14. Adamson, P. M. *et al.* Deuterium metabolic imaging for 3D mapping of glucose metabolism in
381 humans with central nervous system lesions at 3T. *Magn. Reson. Med.* **91**, 39–50 (2024) doi:
382 10.1002/mrm.29830.
- 383 15. Ahmadian, N. *et al.* Human Brain Deuterium Metabolic Imaging at 7 T : Impact of Different
384 [6,6'-²H₂]Glucose Doses. *J. Magn. Reson. Imaging* jmri.29532 (2024) doi:10.1002/jmri.29532
385 doi: 10.1002/jmri.29532.
- 386 16. Purvis, L. A. B. *et al.* OXSA: An open-source magnetic resonance spectroscopy analysis toolbox
387 in MATLAB. *PLOS ONE* **12**, e0185356 (2017) doi: 10.1371/journal.pone.0185356.
- 388 17. Vanhamme, L., van den Boogaart, A. & Van Huffel, S. Improved Method for Accurate and
389 Efficient Quantification of MRS Data with Use of Prior Knowledge. *J. Magn. Reson.* **129**, 35–43
390 (1997) doi: 10.1006/jmre.1997.1244.

- 391 18. Fan, T. W.-M. Metabolite profiling by one- and two-dimensional NMR analysis of complex
392 mixtures. *Prog. Nucl. Magn. Reson. Spectrosc.* **28**, 161–219 (1996) doi: 10.1016/0079-
393 6565(95)01017-3.
- 394 19. Htun, K. T. *et al.* Advanced Molecular Imaging (MRI/MRS/¹H NMR) for Metabolic Information
395 in Young Adults with Health Risk Obesity. *Life* **11**, 1035 (2021) doi: 10.3390/life11101035.
- 396 20. Tkáč, I. *et al.* In vivo ¹H NMR spectroscopy of the human brain at 7 T. *Magn. Reson. Med.* **46**,
397 451–456 (2001) doi: 10.1002/mrm.1213.
- 398 21. Montrazi, E. T., Sasson, K., Agemy, L., Scherz, A. & Frydman, L. Molecular imaging of tumor
399 metabolism: Insight from pyruvate- and glucose-based deuterium MRI studies. *Sci. Adv.* **10**,
400 eadm8600 (2024) doi: 10.1126/sciadv.adm8600.
- 401 22. Mellanby, K. Metabolic Water and Desiccation. *Nature* **150**, 21–21 (1942) doi:
402 10.1038/150021a0.
- 403 23. Sawka, M. N., Chevront, S. N. & Carter, R. Human Water Needs. *Nutr. Rev.* **63**, S30–S39 (2005)
404 doi: 10.1111/j.1753-4887.2005.tb00152.x.
- 405 24. Bøgh, N., Vaeggemose, M., Schulte, R. F., Hansen, E. S. S. & Laustsen, C. Repeatability of
406 deuterium metabolic imaging of healthy volunteers at 3 T. *Eur. Radiol. Exp.* **8**, 44 (2024) doi:
407 10.1186/s41747-024-00426-4.
- 408 25. Jagannathan, R. *et al.* The Oral Glucose Tolerance Test: 100 Years Later. *Diabetes Metab. Syndr.*
409 *Obes. Targets Ther.* **Volume 13**, 3787–3805 (2020) doi: 10.2147/DMSO.S246062.
- 410 26. Graham, M. M., Peterson, L. M. & Hayward, R. M. Comparison of simplified quantitative
411 analyses of FDG uptake. *Nucl. Med. Biol.* **27**, 647–655 (2000) doi: 10.1016/S0969-
412 8051(00)00143-8.
- 413 27. Larson, P. E. Z. *et al.* Investigation of analysis methods for hyperpolarized ¹³C-pyruvate
414 metabolic MRI in prostate cancer patients. *NMR Biomed.* **31**, (2018) doi: 10.1002/nbm.3997.
- 415 28. Daniels, C. J. *et al.* A comparison of quantitative methods for clinical imaging with
416 hyperpolarized ¹³C-pyruvate. *NMR Biomed.* **29**, 387–399 (2016) doi: 10.1002/nbm.3468.

- 417 29. Schwarz, J.-M., Clearfield, M. & Mulligan, K. Conversion of Sugar to Fat: Is Hepatic de Novo
418 Lipogenesis Leading to Metabolic Syndrome and Associated Chronic Diseases? *J. Osteopath.*
419 *Med.* **117**, 520–527 (2017) doi: 10.7556/jaoa.2017.102.
420
421